BioCryst Prescription drugs, Inc. (NASDAQ:BCRX) Cantor International Healthcare Convention 2025 September 4, 2025 9:45 AM EDT
Firm Individuals
Charles Gayer – President
Babar Ghias – CFO & Head of Company Growth
Convention Name Individuals
Steven Seedhouse – Cantor Fitzgerald & Co., Analysis Division
Presentation
Steven Seedhouse
MD & Biotechnology Analyst
Good morning, everybody, and thanks a lot for becoming a member of us for our subsequent session. I am Steve Seedhouse with the Cantor Biotech workforce. It is actually a privilege to welcome our subsequent collaborating firm on the convention, BioCryst Prescription drugs. Because of everybody on the webcast and within the room for being right here additionally.
And I am joined on stage by CFO, Babar Ghias and President and CCO, excuse me. And I assume there’s loads of change within the title. So we’ll say rising CEO as properly, Charlie Gayer. Thanks a lot for being right here. We’d like to cross the mic over and simply ask for an intro to BioCryst, present state of affairs, outlook for the remainder of the 12 months for some opening feedback, after which we’ll dive proper into Q&A.
Charles Gayer
President
Certain. Thanks, Steve. We’re actually happy to be right here. Babar and I will probably be making some forward-looking statements. These statements have dangers. You could find these dangers in our SEC filings at bioocryst.com.
BioCryst is in a very thrilling place proper now, and I am excited to be taking on CEO in January as a result of we now have ORLADEYO, which goes to promote $580 million to $600 million globally this 12 months and is rising at a couple of 20% CAGR. We’re within the course of of really promoting our European enterprise, which can shut early in October, and that is going to provide us a chance. That is really a enterprise that, whereas commercially was going very properly, was not worthwhile for us. And so the $250 million we get from that deal goes to
